面对2025年复杂多变的行业环境，和元生物积极应对、主动出击。业绩快报显示，报告期内，公司一方 面积极拓展市场并实现业务延伸，推动各主营业务板块实现收入不同程度的增长；另一方面，公司增加 研发投入并注重技术应用转化，通过引入AI+技术提升研发效率，推进数字化转型促进管理升级，以及 工艺改进推动国产替代等长效措施，公司的各项运营成本和期间费用较上年同期有所下降，综合毛利率 得到改善，"降本增效"行动取得了阶段性成效。 在内部挖潜的同时，和元生物也积极通过资本运作完善产业链布局。2月5日，该公司发布公告，拟参与 设立产业并购基金和元弘盛产业投资基金合伙企业，重点投资于细胞与基因治疗产业链及其相关上下游 相关行业。 （文章来源：证券日报） 本报讯 2月26日，国内细胞与基因治疗（CGT）赛道企业和元生物技术（上海）股份有限公司（以下简 称"和元生物"）发布2025年业绩快报。该公司2025年实现营业收入2.68亿元，同比增长7.86%；净亏损 2.21亿元，同比减少亏损1.01亿元，经营基本面呈现明显的修复态势，彰显出在行业调整周期中的发展 韧性。 这份成绩单背后，是和元生物十余年来在细胞与基因治疗领域的深耕与积淀 ...

Core Insights - The "White Paper on the Coordinated Development of Manufacturing and Service Industries in Guangdong Province" was released, highlighting the accelerated collaboration between these sectors in Guangdong, with multiple indicators leading the nation [1] - By 2025, Guangdong's GDP is projected to reach 14.58 trillion yuan, maintaining its position as the top province in China for 37 consecutive years [1] - The manufacturing value-added ratio is expected to reach one-third, while the service industry's value-added will account for nearly 60% of GDP, continuing its national leadership for 41 years [1] Industry Development - Guangdong is strategically positioning itself in future industries such as sixth-generation mobile communications, embodied intelligence, cell and gene therapy, hydrogen energy, and advanced nuclear energy [1] - The region's innovation capability in technology services has ranked first nationally for nine consecutive years, with the "Shenzhen-Hong Kong-Guangzhou" tech cluster innovation index topping the global rankings last year [1] - Guangdong boasts 47 national-level industrial design centers, with the highest number of accounting, legal, tax, and inspection institutions in the country [1] Future Directions - During the "14th Five-Year Plan" period, Guangdong aims to transition products from standardization to personalization, intelligence, and quality, extending the industry into high-value segments like R&D design and brand management [2] - The province plans to cultivate a number of new collaborative scenarios with demonstrative effects, enhancing the diversity of industrial collaboration models and the vitality of the ecosystem [2] - Guangdong will support enterprises in participating in the formulation of international standards, aiming for a transition from "Guangdong goods worldwide" to "Guangdong technology + standards + services globally" [2]

Core Viewpoint - The article discusses the establishment of a new 500 million RMB industrial merger fund by He Yuan Biotechnology, highlighting the growing trend of merger funds in the Chinese market and the supportive policies driving this growth [2][3][8]. Group 1: Fund Establishment - He Yuan Biotechnology announced its plan to co-establish the He Yuan Hongsheng Industrial Investment Fund with Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. and other partners, with a total fund size of 500 million RMB [5]. - He Yuan Biotechnology will contribute up to 100 million RMB as a limited partner (LP), accounting for 20% of the fund, while the general partners will contribute 5 million RMB, representing 1% [5]. - The fund's duration is set for 8 years, with the first 4 years designated for investment and the latter 4 years for exit [5]. Group 2: Investment Focus - The fund will focus on the cell and gene therapy (CGT) industry chain and related upstream and downstream fields, aiming to provide systematic and efficient tools for industrial integration [6]. - He Yuan Biotechnology aims to leverage Hongsheng Junhao's resources and advantages in equity investment to create a "dedicated strategic platform" around its industrial ecosystem [6]. Group 3: Market Trends - The establishment of this fund reflects a broader trend in the merger fund industry, which has seen significant growth since 2025, driven by supportive policies such as the "New National Nine Articles" and "Merger Six Articles" [8]. - In 2025, 305 listed companies participated in the establishment of 321 industrial merger funds, with a total fundraising scale of approximately 297.51 billion RMB, showing a notable increase from 2024 [8]. - The merger and acquisition (M&A) market is experiencing a surge, with significant transactions across various sectors, including consumer goods, manufacturing, resources, and biomedicine [9]. Group 4: Policy Support - The Chinese government is enhancing support for the merger fund sector, with plans to establish a national-level merger fund and promote innovation and entrepreneurship [10]. - New merger funds are increasingly concentrated in strategic sectors such as advanced manufacturing, healthcare, artificial intelligence, automotive, new materials, and semiconductors, indicating their role in implementing national industrial policies [10]. - In 2025, the transaction volume of China's M&A market exceeded 400 billion USD, marking a 47% year-on-year increase, with expectations for continued activity in high-tech and new energy sectors in 2026 [10].

该平台以"赋能CGT市场化、标准化发展"为核心定位，聚焦"质粒—病毒载体—细胞药物"全产业链布局，将打造符合GMP标准的生产与检测体系，解决行业 规模化生产难度大、成本高、标准不统一、市场化经验不足等痛点，加速技术转化落地，构建可持续商业生态，目标成为全国具备创新示范效应的CGT公共 服务平台。 近日，卫光生物发布对外投资公告，拟联合深圳市深业生物医药产业发展有限公司、深圳细胞谷生物医药有限公司及深圳赛桥生物创新技术有限公司，共同 出资设立深圳市羲和生命科技有限责任公司，打造深圳市细胞与基因治疗市场化公共服务平台。羲和生命科技初始注册资本为1亿元人民币，其中卫光生物 作为第一大股东，认缴出资4000万元，持股比例为40%。 市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

Group 1: Investor Relations Activity - The investor relations activity included a meeting with analysts and representatives from various financial institutions [2][3] - Key participants included analysts from New Fortune Magazine, Shenwan Hongyuan Securities, and several private equity funds [2][3] Group 2: Company Overview and Product Insights - The company is focused on PVP series products, which experienced price increases due to the European energy crisis and the Russia-Ukraine conflict, but is expected to stabilize in 2026 [3][4] - In 2025, the company sold approximately 4,000 tons of PVP products in the new energy sector, with a projected 20% increase in 2026 [4] - The company also sold about 200 tons of PVP products in the photovoltaic industry in 2025, with expected growth in 2026 [4] Group 3: Product Development and Strategic Goals - The company is transitioning from "capacity leading" to "technology leading + service leading" as part of its strategic upgrade plan initiated in 2025 [4][5] - The company is the only manufacturer using a non-benzene process for producing its products, which provides a competitive edge [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes shareholder communication and has engaged with its top ten shareholders regarding operational and governance matters [6][7] - The controlling shareholder and their associates are optimistic about the company's long-term prospects and have intentions to increase their shareholding [7] Group 5: Medical Sector Investments - The company has strategically invested in five biotechnology firms focusing on innovative drug development, with several products advancing through regulatory stages [6][7] - One product is in the NDA approval stage, two are in Phase II clinical trials, and several others have received IND approvals in China and the U.S. [7]

Core Insights - Shanghai aims to significantly promote technological innovation by 2025, with a focus on enhancing support policies for leading and high-growth enterprises [1] - The city's R&D expenditure is projected to reach approximately 4.5% of its GDP by 2025, with strategic emerging industries expected to grow by 6.5% [1] - The scale of the integrated circuit, biomedicine, and artificial intelligence industries is anticipated to exceed 2 trillion yuan [1] Group 1 - By the end of 2025, Shanghai is expected to have over 23,000 innovative small and medium-sized enterprises (SMEs) and more than 13,000 specialized and innovative SMEs [1] - The number of "little giant" enterprises, which are specialized and innovative, is projected to surpass 1,000 [1] - Shanghai has initiated 18 high-quality incubators covering emerging industries such as optoelectronics, intelligent sensing, synthetic biology, and cell and gene therapy [1] Group 2 - In 2026, Shanghai plans to strengthen the role of innovation entities and improve the cultivation system for innovative enterprises, including technology-based SMEs and high-growth companies [1] - The city expects to add over 50 advanced intelligent factories and actively foster new models and business formats [1]

Economic Development and Growth Targets - Shanghai's GDP is projected to reach 5.67 trillion yuan by 2025, with a growth rate of 5.4% compared to the previous year, achieving annual and "14th Five-Year" economic growth targets [2] - The GDP growth target for 2023 is set at around 5%, focusing on expanding effective demand and promoting consumption and investment [2] Foreign Investment and Trade - By the end of last year, Shanghai had recognized 1,076 regional headquarters of multinational companies and 636 foreign R&D centers, with over 6,300 new foreign enterprises expected to be established by 2025, marking a 6.8% year-on-year increase [3] - The foreign trade import and export scale is anticipated to exceed 4.5 trillion yuan by 2025, with a 19.8% growth in contracted foreign investment [3] Industrial Development and Innovation - Shanghai's industrial output value surpassed 4 trillion yuan last year, with plans to target new sectors such as smart terminals and commercial aerospace during the "15th Five-Year" period [4] - The city aims to increase R&D expenditure to about 4.5% of GDP by 2025, with a focus on enhancing basic research investment from 7.9% to around 12% [4] Employment and Skills Development - Shanghai plans to create over 600,000 new jobs by 2026, with a focus on supporting youth employment and addressing the impact of AI on job markets through "AI + employment" initiatives [6] - The city will host the 48th World Skills Competition to promote new skills and enhance vocational training aligned with industry needs [6] Elderly Care and Community Services - Shanghai has established 122 smart elderly care facilities, aiming to enhance technology-driven services and community care [7] - The city has introduced guidelines for building senior-friendly shopping environments, which have been well-received by the elderly community [7]

Core Viewpoint - Shanghai is focusing on developing advanced manufacturing and future industries, leveraging its strengths in AI, talent supply, and industrial collaboration to enhance its innovation ecosystem [1][2]. Group 1: Advanced Manufacturing and AI Development - Shanghai plans to establish 500 advanced intelligent factories and achieve an industrial robot application density of 600 units per 10,000 people during the 14th Five-Year Plan period [1]. - The city accounts for nearly 10% of the national computing power and has launched 138 registered large models, along with breakthroughs in several intelligent computing chips [1]. - Shanghai has issued 1 billion yuan annually in computing power, corpus, and model vouchers to support AI initiatives [1]. Group 2: Future Industry Focus - Shanghai has created a cluster for brain-computer interface and other future industries, achieving significant breakthroughs and being the first in the country to establish a systematic layout [2]. - The city is concentrating on quantum computing, cell and gene therapy, 6G, and controlled nuclear fusion, implementing a "four-in-one" nurturing mechanism for future industries [2]. - A future industry fund with a total scale of 15 billion yuan will be established to guide social capital towards early, small, hard technology, and long-term projects [2]. Group 3: Targeted Industry Development - Shanghai will implement differentiated nurturing plans for key sectors, accelerating product engineering and industrialization in fields like cell and gene therapy and brain-computer interfaces [3]. - Support will be provided for optimizing product design and expanding application scenarios in fields like silicon-based photonics and 6G, which are in the R&D phase [3]. - The city aims to tackle technical challenges in emerging fields such as quantum technology and regenerative medicine, which are still in the exploratory phase [3].

该项目拟建设以国内市场为核心基础、同步辐射全球市场的细胞与基因治疗(CGT)市场化公共服务平 台，以"赋能CGT市场化、标准化发展"为核心定位，聚焦"质粒-病毒载体-细胞药物"全产业链布局，打 造符合GMP标准的生产与检测体系，打破行业瓶颈，降低产业门槛，加速技术转化，构建可持续发展 的商业生态，打造全国最具创新示范效应的CGT公共服务平台。 该项目的建设实施，是公司立足现有核心优势，从血液制品领域向生物医药前沿赛道延伸拓展的重要战 略举措，有利于公司进一步完善生物医药领域战略布局，培育新的业务增长点，增强公司差异化竞争优 势，是公司实现战略升级、推动高质量发展的重要抓手。 卫光生物（002880）(002880.SZ)发布公告，公司拟与深圳市深业生物医药产业发展有限公司(简称深业 生物)、深圳细胞谷生物医药有限公司(简称深圳细胞谷)及深圳赛桥生物创新技术有限公司(简称赛桥生 物)共同出资设立深圳市羲和生命科技有限责任公司(暂定名，以工商部门最终登记结果为准。简称羲和 生命科技或项目公司)，建设深圳市细胞与基因治疗市场化公共服务平台。羲和生命科技初始注册资本 为1亿元，公司认缴4000万元，占羲和生命科技股权 ...

Core Viewpoint - Changping District aims to enhance its role in supporting the capital's development by building modern industrial clusters and focusing on innovation-driven growth [1] Group 1: Industrial Development - Changping will strengthen three leading industries: healthcare, advanced energy, and advanced manufacturing [1] - The district plans to expand emerging industries such as beautiful health, hydrogen energy, energy storage, energy internet, medical devices, and robotics [1] - Future industries will be strategically developed, including brain science and brain-computer interfaces, 6G technology, and cell and gene therapy [1] Group 2: Urban Integration and Quality of Life - The district will promote urban-rural integration and enhance urban renewal through the third round of the "Huitian Action Plan" [1] - Efforts will be made to create the Beijing North Ecological Corridor, improving the carrying capacity and livability of the new city [1]